Home Archive Vol.41, No.1, 2015 Final Height in Children with Idiopathic Growth Hormone Deficiency treated with Growth Hormone: Albanian experience

Final Height in Children with Idiopathic Growth Hormone Deficiency treated with Growth Hormone: Albanian experience

A. GJIKOPULLI(1), Lindita Grimci(1), L. Kollcaku(1), Sonila Tomori(1), P. CULLUFI(1), P. Hoxha(1), Zamira Ylli(2)

(1)Division of Pediatric Endocrinology, Department of Pediatrics, University Hospital Centre “Mother Teresa”, Albania, (2)Department of Laboratory, University Hospital Centre “Mother Teresa”, Albania

    Abstract: Objective- To evaluate the efficiency of recombinant growth hormone for increasing adult height in children treated for idiopathic growth hormone deficiency and to evaluate the prognostic factor for height at the end of treatment. Design- Observational follow up study. Setting- Population based registry. Participants- All Albanian children diagnosed with idiopathic growth hormone deficiency who had attained final height. Their treatment started between 2001 and 2011. Main outcome measures- Annual changes in height, and change in height between the start of treatment and adulthood; the importance of the factors that influence on final height. Results- Adult height was obtained for 83 (55%) patients. The mean dose of growth hormone at start of treatment was 0.21 IU/kg/week for 29 patients and 0.24 IU/week for 54 patients. Height gain was 2.41±1.19 z-scores, resulting in an adult height of -1.98±1.12 z-score (girls, -2.05±1.27 z-score; boys, -1.95±1.20 z-score). Patients who completed the treatment gained 2.40±1.13 z-score of height in 4.0±2.0 years. Most of the variation in height gain was explained by regression towards the mean, patients characteristics, and delay in starting puberty. Conclusion- Nearly all our patients with idiopathic growth hormone deficiency treated with growth hormone were able to achieve their genetic height potential. Despite starting treatment late, they managed to gain 2.40±1.13 HAZ score in height and the final height for majority of them (61.5%) was within the target height range. It was found that the final height had good correlation with the prediction height, HAZ score at beginning of treatment, change of HAZ score during the puberty, duration of treatment with GH, and pubertal stage at the start of therapy.
    Keywords: Idiopathic Growth Hormone Deficiency, HAZ (Height for Age Z-score), Final height, Growth hormone therapy

DOI 10.12865/CHSJ.41.01.03


All articles in this issue

Volume 41 Issue 1 2015